SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JNJ-38158471

Item No. 41361

CAS Registry No.:	951151-97-6
Formal Name:	N-[4-[[6-amino-5-[(methoxyimino) methyl]-4-pyrimidinyl]oxy]-2-chlorophenyl]-N′-ethyl-urea
MF:	$C_{15}H_{17}ClN_6O_3$
FW:	364.8
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JNJ-38158471 is supplied as a solid. A stock solution may be made by dissolving the JNJ-38158471 in the solvent of choice, which should be purged with an inert gas. JNJ-38158471 is slightly soluble (0.1-1 mg/ml) in DMSO.

Description

JNJ-38158471 is an inhibitor of VEGFR2 (IC_{50} = 42 nM).[1] It is selective for VEGFR2 over the PDGFR family kinases CSF-1 receptor tyrosine kinase (FMS), PDGFRα, FMS-related tyrosine kinase 3 (FLT3), and KIT (IC_{50}s = 624, 1,109, 4,810, and 511 nM, respectively) and VEGFR family kinases VEGFR1 and VEGFR3 (IC_{50}s = 4,451 and 1,112 nM, respectively) but does inhibit RET (IC_{50} = 183 nM). JNJ-38158471 (10, 100, or 500 nM) decreases VEGF-induced phosphorylation of VEGFR2 in serum-starved human umbilical vein endothelial cells (HUVECs). It inhibits VEGF-induced migration in HUVECs when used at a concentration of 1 µM. JNJ-38158471 (100 mg/kg) reduces Vegf-induced corneal neovascularization in mice. It decreases tumor size in an HCT116 colorectal cancer mouse xenograft model when administered at doses ranging from 10 to 200 mg/kg per day. JNJ-38158471 (100 mg/kg per day) reduces polyp number in an *Apc*$^{+/Min\text{-}FCCC}$ mouse model of spontaneous colorectal adenoma.

Reference

1. LaMontagne, K.R., Butler, J., Borowski, V.B., *et al.* A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. *Angiogenesis* **12(3)**, 287-296 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM